Aligos Therapeutics Q2 EPS $(0.43) Beats $(0.49) Estimate, Sales $2.59M Down From $3.69M YoY
Portfolio Pulse from Benzinga Newsdesk
Aligos Therapeutics reported Q2 losses of $(0.43) per share, beating the analyst consensus estimate of $(0.49) by 12.24%. This is an 8.51% increase over losses from the same period last year. However, the company's sales decreased by 29.81% to $2.59 million from $3.69 million YoY.
August 04, 2023 | 2:35 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Aligos Therapeutics reported better than expected Q2 losses but saw a significant decrease in sales YoY.
While Aligos Therapeutics managed to beat the analyst consensus estimate for Q2 losses, the significant decrease in sales YoY could potentially offset any positive sentiment from the earnings beat. This mixed result makes it difficult to predict the short-term price direction.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100